Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008
Predictors of treatment failure among pulmonary tuberculosis patients in Pakistan Source: International Congress 2019 – Tuberculosis: from diagnosis to complications Year: 2019
Statin with standard antituberculosis regimen and mortality in hospitalized pulmonary tuberculosis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment Source: International Congress 2017 – MDRTB: detection and management Year: 2017
Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Directly observed therapy versus self administered therapy for patients of new smear positive pulmonary tuberculosis during hospitalisation period Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Forecasting the risk of medicinal complications from the chemical therapy in patients with multi-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011
Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs Source: Eur Respir J 2007; 30: Suppl. 51, 657s Year: 2007
Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006
Effectiveness of the intensive phase of chemotherapy in pulmonary TB patients with primary drug resistance Source: Eur Respir J 2006; 28: Suppl. 50, 290s Year: 2006
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
Investigating trends in antituberculosis (anti-TB) drug resistance among treated patients of a university respiratory infections unit in Greece Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010
Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006